{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:57:40Z","timestamp":1758052660774,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.clinbiochem.2006.09.003","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T10:30:32Z","timestamp":1158661832000},"page":"6-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serum soluble Fas levels in patients with autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"Sahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ayd\u0131ntug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Tunc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tutkak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Naz\u0131ro\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2006.09.003_bib1","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3748\/wjg.v10.i21.3151","article-title":"Role of soluble Fas ligand in autoimmune diseases","volume":"10","author":"Li","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/39.12.1341","article-title":"Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis","volume":"39","author":"Stummvoll","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib4","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","article-title":"Protection from Fas mediated apoptosis by a soluble form of the Fas molecule","volume":"263","author":"Cheng","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00403-005-0616-2","article-title":"Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese","volume":"297","author":"Hao","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s004030000170","article-title":"Soluble Fas levels in patients with systemic sclerosis","volume":"292","author":"Bianchi","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib7","first-page":"915","article-title":"Detection of the soluble form of Fas ligand (sFasL) and sFas in the saliva from patients with Sjogren's syndrome","volume":"23","author":"Nakamura","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1023\/A:1016040925295","article-title":"Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases","volume":"22","author":"Christensson","year":"2002","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/art.1780400112","article-title":"Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis","volume":"40","author":"Hasunuma","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.1780400617","article-title":"Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases","volume":"40","author":"Nozawa","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10067-004-0909-4","article-title":"The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis","volume":"223","author":"Ates","year":"2004","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.1780381206","article-title":"Lack of correlation between serum soluble Fas\/APO-1 levels and autoimmune disease","volume":"38","author":"Goel","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/art.1780381205","article-title":"Levels of soluble Fas\/APO-1\/CD 95 in systemic lupus erythematosus and juvenile rheumatoid arthritis","volume":"38","author":"Knipping","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib17","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","article-title":"Preliminary criteria for clinical remission in rheumatoid arthritis","volume":"24","author":"Pinals","year":"1981","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib18","first-page":"367","article-title":"A modified scleroderma skin scoring method","volume":"4","author":"Kahaleh","year":"1986","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780290501","article-title":"Sj\u00f6gren\u2019s syndrome proposed criteria for classification","volume":"29","author":"Fox","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.clinbiochem.2006.09.003_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0049-0172(91)90026-V","article-title":"Classification of disease: osteoarthritis","volume":"20","author":"Altman","year":"1991","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib23","first-page":"103","article-title":"Reference intervals of serum soluble APO-1 (Fas\/CD95) concentrations in healthy adults","volume":"36","author":"Choi","year":"2006","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib24","first-page":"109","article-title":"Clinical significance of serum IL-18 determination in rheumatoid arthritis","volume":"52","author":"Sato","year":"2004","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2249.1997.d01-901.x","article-title":"Serum levels of soluble Fas\/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases","volume":"107","author":"Jodo","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1191\/096120300678828145","article-title":"Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus","volume":"9","author":"Al Maini","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI118851","article-title":"Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma","volume":"98","author":"Sgonc","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s004030050288","article-title":"Serum levels of soluble Fas\/APO-1 receptor are increased in systemic sclerosis","volume":"290","author":"Wetzig","year":"1998","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2567.2005.02192.x","article-title":"Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis","volume":"116","author":"Takata-Tomokuni","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib30","first-page":"309","article-title":"Expression of ductal Fas in sialoadenitis of Sj\u00f6gren's syndrome","volume":"14","author":"Matsumuro","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2006.09.003_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF01451286","article-title":"Serum soluble Fas\/APO-1 is increased in patients with primary Sjogren\u2019s syndrome","volume":"17","author":"Fujihara","year":"1998","journal-title":"Clin. Rheumatol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912006002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912006002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:25:14Z","timestamp":1757863514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912006002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":31,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0009912006002840"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.09.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum soluble Fas levels in patients with autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}